Johnson & Johnson (JNJ) 10-Q 4 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jul. 03, 2016	Jul. 29, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	200,406
Current Fiscal Year End Date	--01-01
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jul. 3, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,735,876,843

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jul. 03, 2016	Jan. 03, 2016
Current assets:
Cash and cash equivalents	$ 18,640	$ 13,732
Marketable securities	23,944	24,644
Accounts receivable, trade, less allowances for doubtful accounts $270 (2015, $268)	12,062	10,734
Inventories (Note 2)	8,523	8,053
Prepaid expenses and other	3,122	3,047
Total current assets	66,291	60,210
Property, plant and equipment at cost	37,779	36,648
Less: accumulated depreciation	(21,807)	(20,743)
Property, plant and equipment, net	15,972	15,905
Intangible assets, net (Note 3)	25,694	25,764
Goodwill (Note 3)	22,104	21,629
Deferred taxes on income	5,776	5,490
Other assets	3,977	4,413
Total assets	139,814	133,411
Current liabilities:
Loans and notes payable	1,708	7,004
Accounts payable	6,061	6,668
Accrued liabilities	5,650	5,411
Accrued rebates, returns and promotions	5,259	5,440
Accrued compensation and employee related obligations	2,168	2,474
Accrued taxes on income	690	750
Total current liabilities	21,536	27,747
Long-term debt (Note 4)	24,535	12,857
Deferred taxes on income	2,849	2,562
Employee related obligations	8,359	8,854
Other liabilities	10,062	10,241
Total liabilities	67,341	62,261
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(12,707)	(13,165)
Retained earnings	106,738	103,879
Less: common stock held in treasury, at cost (382,189,000 and 364,681,000 shares)	24,678	22,684
Total shareholders’ equity	72,473	71,150
Total liabilities and shareholders' equity	$ 139,814	$ 133,411

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	Jul. 03, 2016	Jan. 03, 2016
Current assets:
Allowances for doubtful accounts	$ 270	$ 268
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000	4,320,000
Common stock, shares issued	3,119,843	3,119,843
Treasury stock, shares	382,189	364,681

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Income Statement [Abstract]
Sales to customers (Note 9)	$ 18,482	$ 17,787	$ 35,964	$ 35,161
Sales to customers percent to sales	100.00%	100.00%	100.00%	100.00%
Cost of products sold	$ 5,336	$ 5,357	$ 10,665	$ 10,639
Cost of products sold percent to sales	28.90%	30.10%	29.60%	30.20%
Gross profit	$ 13,146	$ 12,430	$ 25,299	$ 24,522
Gross profit percent to sales	71.10%	69.90%	70.40%	69.80%
Selling, marketing and administrative expenses	$ 5,176	$ 5,384	$ 9,864	$ 10,231
Selling marketing and administrative expenses percent to sales	28.00%	30.30%	27.40%	29.10%
Research and development expense	$ 2,264	$ 2,129	$ 4,277	$ 4,028
Research and development expense percent to sales	12.20%	12.00%	11.90%	11.50%
Research and Development in Process	$ 29	$ 0	$ 29	$ 0
Research and development in process percent to sales	0.20%	0.00%	0.10%	0.00%
Interest income	$ (88)	$ (24)	$ (171)	$ (43)
Interest income percent to sales	(0.50%)	(0.10%)	(0.50%)	(0.10%)
Interest expense, net of portion capitalized	$ 190	$ 131	$ 350	$ 269
Interest expense, net of portion capitalized percent to sales	1.10%	0.70%	1.00%	0.70%
Other (income) expense, net	$ 557	$ (931)	$ 518	$ (1,279)
Other (income) expense, net percent to sales	3.00%	(5.30%)	1.40%	(3.60%)
Restructuring (Note 12)	$ 114	$ 0	$ 234	$ 0
Restructuring charge percent to sales	0.60%	0.00%	0.70%	0.00%
Earnings before provision for taxes on income	$ 4,904	$ 5,741	$ 10,198	$ 11,316
Earnings before provision for taxes on income percent to sales	26.50%	32.30%	28.40%	32.20%
Provision for taxes on income (Note 5)	$ 907	$ 1,225	$ 1,744	$ 2,480
Provision for taxes on income perent to sales	4.90%	6.90%	4.90%	7.10%
NET EARNINGS	$ 3,997	$ 4,516	$ 8,454	$ 8,836
Net earnings percent to sales	21.60%	25.40%	23.50%	25.10%
NET EARNINGS PER SHARE (Note 8)
Basic (per share)	$ 1.46	$ 1.63	$ 3.07	$ 3.18
Diluted (per share)	1.43	1.61	3.02	3.13
CASH DIVIDENDS PER SHARE	$ 0.80	$ 0.75	$ 1.55	$ 1.45
AVG. SHARES OUTSTANDING
Basic (shares)	2,745.4	2,772.3	2,751.4	2,777.7
Diluted (shares)	2,794.2	2,812	2,800.9	2,821

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Statement of Comprehensive Income [Abstract]
Net earnings	$ 3,997	$ 4,516	$ 8,454	$ 8,836
Other comprehensive income (loss), net of tax
Foreign currency translation	(295)	903	584	(1,660)
Securities:
Unrealized holding gain (loss) arising during period	156	196	100	311
Reclassifications to earnings	(12)	(24)	(94)	(81)
Net change	144	172	6	230
Employee benefit plans:
Prior service cost amortization during period	(6)	(6)	(10)	(11)
Gain (loss) amortization during period	101	159	207	318
Net change	95	153	197	307
Derivatives & hedges:
Unrealized gain (loss) arising during period	(250)	61	(441)	(134)
Reclassifications to earnings	(10)	(43)	112	(75)
Net change	(260)	18	(329)	(209)
Other comprehensive income (loss)	(316)	1,246	458	(1,332)
Comprehensive income	$ 3,681	$ 5,762	$ 8,912	$ 7,504

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Consolidated Statement of Comprehensive Income [Abstract]
Securities	$ 77	$ 92	$ 3	$ 124
Employee Benefits	56	75	104	151
Derivatives & Hedges	$ 140	$ 9	$ 177	$ 113

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015
CASH FLOW FROM OPERATING ACTIVITIES
Net earnings	$ 8,454	$ 8,836
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	1,791	1,784
Stock based compensation	479	474
Asset write-downs	187	11
Net gain on sale of assets/businesses	(185)	(1,034)
Deferred tax provision	115	284
Accounts receivable allowances	(4)	5
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(1,098)	(1,186)
Increase in inventories	(443)	(537)
Decrease in accounts payable and accrued liabilities	(1,047)	(1,931)
(Increase)/Decrease in other current and non-current assets	(630)	602
(Decrease)/Increase in other current and non-current liabilities	(866)	1,036
NET CASH FLOWS FROM OPERATING ACTIVITIES	6,753	8,344
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(1,396)	(1,308)
Proceeds from the disposal of assets/businesses, net	685	1,193
Acquisitions, net of cash acquired	(730)	(233)
Purchases of investments	(17,511)	(20,813)
Sales of investments	18,775	15,829
Other	(38)	(11)
NET CASH USED BY INVESTING ACTIVITIES	(215)	(5,343)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(4,266)	(4,025)
Repurchase of common stock	(4,751)	(3,094)
Proceeds from short-term debt	118	1,024
Retirement of short-term debt	(4,687)	(345)
Proceeds from long-term debt, net of issuance costs	11,951	3
Retirement of long-term debt	(936)	(21)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	929	506
Other	0	(50)
NET CASH USED BY FINANCING ACTIVITIES	(1,642)	(6,002)
Effect of exchange rate changes on cash and cash equivalents	12	(883)
Increase/(Decrease) in cash and cash equivalents	4,908	(3,884)
Cash and Cash equivalents, beginning of period	13,732	14,523
CASH AND CASH EQUIVALENTS, END OF PERIOD	18,640	10,639
Acquisitions
Fair value of assets acquired	744	477
Fair value of liabilities assumed and noncontrolling interests	(14)	(244)
Net cash paid for acquisitions	$ 730	$ 233

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jul. 03, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements And Other	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. New Accounting Pronouncements Recently Adopted Accounting Pronouncements During the fiscal first quarter of 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-09 Compensation - Stock Compensation: Improvements to Employee Share Based Payment Accounting. The amendments in the update are effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. During the fiscal second quarter of 2016, the Company elected to early adopt this standard. The update requires the following changes to presentation of the financial statements: • All excess tax benefits and deficiencies to be recognized as a reduction or an increase to the provision for taxes on income. Previously, the Company recorded these benefits directly to Retained Earnings. The tax benefit for the Company was $123 million and $288 million for the fiscal second quarter and fiscal six months ended for 2016, respectively. The standard does not permit retroactive presentation of this benefit to prior fiscal years on the Consolidated Statement of Earnings. • The tax benefit or deficiency is required to be classified and presented as a cash flow to/from operating activities. It was previously required to be presented as a cash flow to/from financing activities on the Consolidated Statement of Cash Flows. As permitted in the standard, the Company has elected to adopt this reclassification on a prospective basis and therefore prior fiscal years for the Consolidated Statement of Cash Flows have not been recast for this provision. • Clarifies that all cash payments made to taxing authorities on employees’ share-based compensation should be classified as a cash outflow from financing activities. This reclassification is required to be recast retrospectively. As a result, $262 million and $272 million of cash outflow was reclassified from an operating activity to a financing activity (Proceeds from the exercise of stock options/employee withholding tax on stock awards, net) for the first fiscal six months of 2016 and 2015, respectively. • In the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. This did not have a material impact on the Company's diluted net earnings per share calculation. During the fiscal third quarter of 2015, the FASB issued Accounting Standards Update 2015-16 Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments. The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This update is effective for the Company for all annual and interim periods beginning after December 15, 2015. The amendments in this update should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued. This update did not have a material impact on the Company’s consolidated financial statements. During the fiscal second quarter of 2015, the FASB issued Accounting Standards Update 2015-03: Simplifying the Presentation of Debt Issuance Costs. This update requires capitalized debt issuance costs to be presented as a reduction to the carrying value of debt instead of being classified as a deferred charge, as currently required. This update is effective for the Company for all annual and interim periods beginning after December 15, 2015 and is required to be applied retroactively for all periods presented. This update did not have a material impact on the presentation of the Company’s financial position. During the fiscal second quarter of 2014, the FASB issued amended guidance Accounting Standards Update No. 2014-10: Development Stage Entities: Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entity Guidance in Topic 810, Consolidation. The change in the current guidance will require the Company to determine if it should consolidate one of these entities based on the change in the consolidation analysis. This update to the consolidation analysis became effective for all annual periods and interim reporting periods beginning after December 15, 2015. The adoption of this standard did not have a material impact on the presentation of the Company's consolidated financial statements. Recently Issued Accounting Standards Not Adopted as of July 3, 2016 During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-07 Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The amendments in the update eliminate the requirement that when an investment qualifies for the use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step by step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the application of the equity method. Earlier adoption is permitted for any entity in any interim or annual period. The adoption of this standard is not expected to have a material impact on the presentation of the Company's consolidated financial statements. During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-02 Leases (Topic 842). This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-01 Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities to be measured at fair value with changes in the fair value recognized through net income. The standard amends financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. This update will be effective for the Company for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal second quarter of 2015, the FASB issued Accounting Standards Update 2015-11: Simplifying the Measurement of Inventory. This update requires inventory to be measured at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2016. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. This update will not have a material impact on the presentation of the Company’s financial position. During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-09: Revenue from Contracts with Customers. This standard replaces substantially all current revenue recognition accounting guidance. During the fiscal third quarter of 2015, the FASB approved a one year deferral to the effective date to be adopted by all public companies for all annual periods and interim reporting periods beginning after December 15, 2017. During the fiscal first quarter of 2016, the FASB issued additional guidance and clarification relating to Identifying Performance Obligations, Licensing, and Principal verses Agent Considerations. During the second quarter of 2016, the FASB issued additional guidance and clarification relating to assessing collectability, presentation of sales taxes, noncash consideration, and contract modifications & completed contracts at transition. Early adoption of this standard is permitted but not before the original effective date for all annual periods and interim reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal third quarter of 2014, the FASB issued Accounting Standards Update No. 2014-15: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This standard requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods ending after December 15, 2016. This standard is not expected to have any impact on current disclosures in the financial statements.

Inventories

Inventories	6 Months Ended
	Jul. 03, 2016
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) July 3, 2016 January 3, 2016 Raw materials and supplies $ 952 936 Goods in process 1,984 2,241 Finished goods 5,587 4,876 Total inventories $ 8,523 8,053

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jul. 03, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2015 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) July 3, 2016 January 3, 2016 Intangible assets with definite lives: Patents and trademarks — gross $ 8,633 8,299 Less accumulated amortization 4,974 4,745 Patents and trademarks — net 3,659 3,554 Customer relationships and other intangibles — gross 17,799 17,583 Less accumulated amortization 6,242 5,816 Customer relationships and other intangibles — net 11,557 11,767 Intangible assets with indefinite lives: Trademarks 7,085 7,023 Purchased in-process research and development 3,393 3,420 Total intangible assets with indefinite lives 10,478 10,443 Total intangible assets — net $ 25,694 25,764 Goodwill as of July 3, 2016 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at January 3, 2016 $ 7,240 2,889 11,500 21,629 Goodwill, related to acquisitions 225 — 180 405 Goodwill, related to divestitures — (10 ) — (10 ) Currency translation/Other 50 11 19 80 Goodwill, net at July 3, 2016 $ 7,515 2,890 11,699 22,104 The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 18 years and 24 years, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $576 million and $619 million for the fiscal six months ended July 3, 2016 and June 28, 2015 , respectively. The estimated amortization expense for the five succeeding years approximates $1.2 billion , before tax, per year. Intangible asset write-downs are included in Other (income) expense, net.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 03, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. The Company also uses equity collar contracts to manage exposure to market risk associated with certain equity investments. All three types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features or requirements to post collateral (excluding equity collar contracts) by either the Company or the counter-party. For equity collar contracts, the Company pledged the underlying hedged marketable equity securities to the counter-party as collateral. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of July 3, 2016 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps, interest rate swaps and equity collar contracts of $31.6 billion , $2.3 billion , $2.2 billion , and $0.5 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in Other (income) expense, net for forward foreign exchange contracts, cross currency interest rate swaps, net investment hedges and equity collar contracts. For interest rate swaps designated as fair value hedges, hedge ineffectiveness, if any, is included in current period earnings within interest expense. For the current reporting period, hedge ineffectiveness associated with interest rate swaps was not material. During the fiscal second quarter of 2016, the Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. During the fiscal second quarter of 2016, the change in the carrying value due to remeasurement of these Euro notes resulted in a $116 million pretax gain reflected in foreign currency translation adjustment, within the Consolidated Statements of Comprehensive Income. As of July 3, 2016 , the balance of deferred net losses on derivatives included in accumulated other comprehensive income was $365 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal second quarters in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Second Quarters Ended Cash Flow Hedges By Income Statement Caption July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Sales to customers (3) $ (27 ) 37 (3 ) (30 ) — (1 ) Cost of products sold (3) (178 ) 52 13 47 (2 ) 14 Research and development expense (3) 12 (7 ) (1 ) 7 (1 ) — Interest (income)/Interest expense, net (4) (3 ) 7 7 — — — Other (income) expense, net (3) (5) (54 ) (28 ) (6 ) 19 — 1 Total $ (250 ) 61 10 43 (3 ) 14 The following table is a summary of the activity related to derivatives designated as cash flow hedges for the first fiscal six months in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Six Months Ended Cash Flow Hedges By Income Statement Caption July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Sales to customers (3) $ (27 ) (55 ) (21 ) (71 ) — (2 ) Cost of products sold (3) (222 ) (116 ) (8 ) 116 (6 ) 14 Research and development expense (3) (95 ) (3 ) (96 ) (9 ) (1 ) — Interest (income)/Interest expense, net (4) 9 (29 ) 15 (3 ) — — Other (income) expense, net (3) (5) (106 ) 69 (2 ) 42 (3 ) 1 Total $ (441 ) (134 ) (112 ) 75 (10 ) 13 All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts For the fiscal second quarters ended July 3, 2016 and June 28, 2015 , a loss of $36 million and a gain of $124 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. For the fiscal six months ended July 3, 2016 and June 28, 2015 , a loss of $41 million and a gain of $40 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of July 3, 2016 and January 3, 2016 were as follows: July 3, 2016 January 3, 2016 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 279 — 279 452 Interest rate contracts (2)(4)(7) — 55 — 55 28 Total — 334 — 334 480 Liabilities: Forward foreign exchange contracts (8) — 569 — 569 358 Interest rate contracts (3)(4)(8) — 314 — 314 241 Equity collar contracts (8)(9) — 108 — 108 — Total — 991 — 991 599 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 28 — 28 33 Liabilities: Forward foreign exchange contracts (8) — 62 — 62 41 Available For Sale Other Investments: Equity investments (5) 1,276 — — 1,276 1,494 Debt securities (6) $ — 12,046 — 12,046 8,316 (1) 2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million , which are classified as Level 1. (2) Includes $41 million and $20 million of non-current other assets for July 3, 2016 and January 3, 2016, respectively. (3) Includes $314 million and $239 million of non-current other liabilities for July 3, 2016 and January 3, 2016, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets with the exception of $272 million of current other assets for July 3, 2016 . The carrying amount of the equity investments were $530 million and $528 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized gains were $767 million and $979 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized losses were $21 million and $13 million as of July 3, 2016 and January 3, 2016, respectively. (6) Classified as current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable. (9) Includes $41 million of non-current other liabilities for July 3, 2016 . The Company's cash, cash equivalents and current marketable securities as of July 3, 2016 comprised: July 3, 2016 (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 1,619 — — 1,619 1,619 U.S. Gov't Securities (1) 6,548 1 — 6,549 900 5,648 Other Sovereign Securities (1) 2,494 — — 2,494 1,359 1,135 U.S. Reverse repurchase agreements (1) 11,288 — — 11,288 9,587 1,701 Other Reverse repurchase agreements (1) 1,600 — — 1,600 1,600 Corporate debt securities (1) 4,598 1 — 4,599 1,456 3,142 Money market funds 882 — — 882 882 Time deposits (1) 1,237 — — 1,237 1,237 Subtotal 30,266 2 — 30,268 18,640 11,626 Unrealized Gain Unrealized Loss Gov't securities 10,036 176 — 10,212 — 10,212 Corporate debt securities 1,818 17 (1 ) 1,834 — 1,834 Equity investments 37 246 (11 ) 272 — 272 Subtotal Available for Sale (2) $ 11,891 439 (12 ) 12,318 — 12,318 Total cash, cash equivalents and current marketable securities 18,640 23,944 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as current marketable securities. The estimated fair value was the same as the amortized cost as of January 3, 2016. The contractual maturities of substantially all available for sale securities were from one year to five years at July 3, 2016. Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July 3, 2016 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 1,708 1,708 Non-Current Debt 5.55% Debentures due 2017 999 1,053 1.125% Notes due 2017 703 709 5.15% Debentures due 2018 899 975 1.65% Notes due 2018 609 620 4.75% Notes due 2019 (1B Euro 1.1098) 1,105 1,286 1.875% Notes due 2019 514 528 0.89% Notes due 2019 299 300 1.125% Notes due 2019 698 704 3% Zero Coupon Convertible Subordinated Debentures due in 2020 110 183 2.95% Debentures due 2020 545 585 3.55% Notes due 2021 447 492 2.45% Notes due 2021 348 371 1.65% Notes due 2021 997 1,015 0.250% Notes due 2022 (1B Euro 1.1098) 1,105 1,123 6.73% Debentures due 2023 249 335 3.375% Notes due 2023 808 905 2.05% Notes due 2023 497 510 0.650% Notes due 2024 (750MM Euro 1.1098) 827 848 5.50% Notes due 2024 (500 MM GBP 1.3418) 664 879 2.45% Notes due 2026 1,989 2,063 1.150% Notes due 2028 (750MM Euro 1.1098) 823 857 6.95% Notes due 2029 296 444 4.95% Debentures due 2033 497 643 4.375% Notes due 2033 857 1,039 1.650% Notes due 2035 (1.5B Euro 1.1098) 1,645 1,811 3.55% Notes due 2036 986 1,096 5.95% Notes due 2037 990 1,472 5.85% Debentures due 2038 695 1,031 4.50% Debentures due 2040 537 680 4.85% Notes due 2041 296 387 4.50% Notes due 2043 495 617 3.70% Notes due 2046 1,970 2,251 Other 36 36 Total Non-Current Debt $ 24,535 27,848 The weighted average effective interest rate on non-current debt is 3.30% . The excess of the estimated fair value over the carrying value of debt was $1.7 billion at January 3, 2016. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	6 Months Ended
	Jul. 03, 2016
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the first fiscal six months of 2016 and 2015 were 17.1% and 21.9% , respectively. In the fiscal six months of 2016, the Company had higher income in lower tax jurisdictions relative to higher tax jurisdictions as compared to 2015, which decreased the effective tax rate by approximately 1.7% . As described in Note 1, the Company adopted a new accounting standard for the reporting of tax benefits on share-based compensation. The adoption of this new standard reduced the tax rate for the first six months of fiscal 2016 by approximately 2.8% versus 2015. The remainder of the change from prior year was primarily related to the U.S. Research & Development tax credit and the Controlled Foreign Corporation look-through provisions, which were not enacted into law until the fiscal fourth quarter of 2015, and the settlement of certain open tax positions in several international jurisdictions. As of July 3, 2016 , the Company had approximately $3.1 billion of liabilities from unrecognized tax benefits. The Company believes it is possible that audits may be completed by tax authorities in some jurisdictions over the next twelve months. The Company is not able to provide a reasonably reliable estimate of the timing of any future tax payments relating to uncertain tax positions.

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits	6 Months Ended
	Jul. 03, 2016
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits	PENSIONS AND OTHER POSTRETIREMENT BENEFITS Components of Net Periodic Benefit Cost Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal second quarters of 2016 and 2015 include the following components: Fiscal Second Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Service cost $ 226 249 55 65 Interest cost 233 248 39 46 Expected return on plan assets (493 ) (455 ) (1 ) (1 ) Amortization of prior service cost/(credit) (1 ) 1 (8 ) (9 ) Recognized actuarial losses 124 187 34 50 Curtailments and settlements 4 — — — Net periodic benefit cost $ 93 230 119 151 Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the first fiscal six months of 2016 and 2015 include the following components: Fiscal Six Months Ended Retirement Plans Other Benefit Plans (Dollars in Millions) July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Service cost $ 452 497 110 129 Interest cost 466 497 79 93 Expected return on plan assets (985 ) (910 ) (3 ) (3 ) Amortization of prior service cost/(credit) — 1 (16 ) (17 ) Recognized actuarial losses 248 374 68 100 Curtailments and settlements 5 4 — — Net periodic benefit cost $ 186 463 238 302 Company Contributions For the fiscal six months ended July 3, 2016 , the Company contributed $283 million and $14 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jul. 03, 2016
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 3, 2016 $ (8,435 ) 604 (5,298 ) (36 ) (13,165 ) Net change 584 6 197 (329 ) 458 July 3, 2016 $ (7,851 ) 610 (5,101 ) (365 ) (12,707 ) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 03, 2016
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal second quarters ended July 3, 2016 and June 28, 2015 : Fiscal Second Quarters Ended (Shares in Millions) July 3, 2016 June 28, 2015 Basic net earnings per share $ 1.46 1.63 Average shares outstanding — basic 2,745.4 2,772.3 Potential shares exercisable under stock option plans 146.3 151.4 Less: shares which could be repurchased under treasury stock method (99.2 ) (113.9 ) Convertible debt shares 1.7 2.2 Average shares outstanding — diluted 2,794.2 2,812.0 Diluted net earnings per share $ 1.43 1.61 The diluted net earnings per share calculation for both the fiscal second quarters ended July 3, 2016 and June 28, 2015 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for both the fiscal second quarters ended July 3, 2016 and June 28, 2015 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive. The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal six months ended July 3, 2016 and June 28, 2015 : Fiscal Six Months Ended (Shares in Millions) July 3, 2016 June 28, 2015 Basic net earnings per share $ 3.07 3.18 Average shares outstanding — basic 2,751.4 2,777.7 Potential shares exercisable under stock option plans 145.8 151.4 Less: shares which could be repurchased under treasury stock method (98.0 ) (110.3 ) Convertible debt shares 1.7 2.2 Average shares outstanding — diluted 2,800.9 2,821.0 Diluted net earnings per share $ 3.02 3.13 The diluted net earnings per share calculation for both the fiscal six months ended July 3, 2016 and June 28, 2015 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for both the fiscal six months ended July 3, 2016 and June 28, 2015 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive.

Segments of Business and Geogra

Segments of Business and Geographic Areas	6 Months Ended
	Jul. 03, 2016
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Second Quarters Ended (Dollars in Millions) July 3, June 28, Percent Change Consumer United States $ 1,384 1,355 2.1 % International 2,035 2,128 (4.4 ) Total 3,419 3,483 (1.8 ) Pharmaceutical United States 5,144 4,543 13.2 International 3,510 3,403 3.1 Total 8,654 7,946 8.9 Medical Devices United States 3,044 3,013 1.0 International 3,365 3,345 0.6 Total 6,409 6,358 0.8 Worldwide United States 9,572 8,911 7.4 International 8,910 8,876 0.4 Total $ 18,482 17,787 3.9 % Fiscal Six Months Ended (Dollars in Millions) July 3, June 28, Percent Change Consumer United States $ 2,742 2,714 1.0 % International 3,872 4,159 (6.9 ) Total 6,614 6,873 (3.8 ) Pharmaceutical United States 10,081 8,914 13.1 International 6,751 6,758 (0.1 ) Total 16,832 15,672 7.4 Medical Devices United States 6,070 5,975 1.6 International 6,448 6,641 (2.9 ) Total 12,518 12,616 (0.8 ) Worldwide United States 18,893 17,603 7.3 International 17,071 17,558 (2.8 ) Total $ 35,964 35,161 2.3 % INCOME BEFORE TAX BY SEGMENT Fiscal Second Quarters Ended (Dollars in Millions) July 3, June 28, Percent Change Consumer $ 571 317 80.1 % Pharmaceutical (1) 3,687 4,122 (10.6 ) Medical Devices (2) 939 1,584 (40.7 ) Segments operating profit 5,197 6,023 (13.7 ) Less: Expense not allocated to segments (3) 293 282 Worldwide income before tax $ 4,904 5,741 (14.6 )% Fiscal Six Months Ended (Dollars in Millions) July 3, 2016 June 28, 2015 Percent Change Consumer $ 1,137 961 18.3 % Pharmaceutical (1) 7,031 7,084 (0.7 ) Medical Devices (2) 2,515 3,805 (33.9 ) Segments operating profit 10,683 11,850 (9.8 ) Less: Expense not allocated to segments (3) 485 534 Worldwide income before taxes $ 10,198 11,316 (9.9 )% (1) Includes litigation expense of $136 million recorded in the fiscal six months of 2015. Includes a gain of $981 million recorded in the fiscal second quarter and first fiscal six months of 2015 from the divestiture of the U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution. Includes a positive adjustment of $539 million and $403 million to previous reserve estimates in the fiscal six months of 2016 and 2015, respectively. Includes a positive adjustment of $342 million and $199 million to previous reserve estimates in the fiscal second quarter of 2016 and 2015, respectively. (2) Includes a restructuring charge of $141 million and $278 million in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $570 million and $676 million recorded in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $134 million in the fiscal second quarter of 2015 and a net litigation gain of $404 million primarily related to a litigation settlement agreement with Guidant recorded in the fiscal six months of 2015. The fiscal six months of 2015 included $148 million for costs associated with the DePuy ASR TM Hip program. (3) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Second Quarters Ended (Dollars in Millions) July 3, 2016 June 28, 2015 Percent Change United States $ 9,572 8,911 7.4 % Europe 4,090 4,151 (1.5 ) Western Hemisphere, excluding U.S. 1,542 1,501 2.7 Asia-Pacific, Africa 3,278 3,224 1.7 Total $ 18,482 17,787 3.9 % Fiscal Six Months Ended (Dollars in Millions) July 3, 2016 June 28, 2015 Percent Change United States $ 18,893 17,603 7.3 % Europe 7,937 8,191 (3.1 ) Western Hemisphere, excluding U.S. 2,873 3,140 (8.5 ) Asia-Pacific, Africa 6,261 6,227 0.5 Total $ 35,964 35,161 2.3 %

Business Combinations and Dives

Business Combinations and Divestitures	6 Months Ended
	Jul. 03, 2016
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES Subsequent to the quarter the Company completed the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal products for $3.3 billion in cash. The Company is in the process of finalizing the purchase price allocation. During the fiscal second quarter of 2016, the Company completed the acquisitions of NeuWave Medical, Inc., a privately-held medical device company that manufactures and markets minimally invasive soft tissue microwave ablation systems and NeoStrata Company, Inc., a global leader in dermocosmetics. Additionally, during the fiscal second quarter of 2016, the Company completed the divestiture of its controlled substance raw material and active pharmaceutical ingredient (API) business. The proceeds from the divestiture were $650 million . During the fiscal second quarter of 2015, the Company completed the divestiture of its U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution for approximately $1.05 billion . The pre-tax gain on the divestiture was $981 million and was recognized in Other (income) expense, net. During the fiscal first quarter of 2015, the Company acquired XO1 Limited, a privately-held biopharmaceutical company developing an anti-thrombin antibody.

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jul. 03, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of July 3, 2016, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, the PINNACLE ® Acetabular Cup System, pelvic meshes, RISPERDAL ® , XARELTO ® and JOHNSON'S ® Baby Powder. As of July 3, 2016, in the U.S. there were approximately 2,900 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, 9,100 with respect to the PINNACLE ® Acetabular Cup System, 50,100 with respect to pelvic meshes, 13,000 with respect to RISPERDAL ® , 13,900 with respect to XARELTO ® and 1,700 with respect to JOHNSON'S ® Baby Powder. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR ™ Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. This settlement covered approximately 8,000 patients. In February 2015, DePuy reached an additional agreement, which effectively extends the existing settlement program to ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 1, 2015. This second agreement is estimated to cover approximately 1,800 additional patients. The estimated cost of these agreements is covered by existing accruals. This settlement program is expected to bring to a close significant ASR Hip litigation activity in the United States. However, many lawsuits in the United States will remain, and the settlement program does not address litigation outside of the United States. In Australia, a settlement has been reached with representatives of a class action lawsuit pending in the Federal Court of New South Wales that resolves the claims of the majority of ASR Hip patients in that country. The Company continues to receive information with respect to potential costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the DePuy ASR™ Hip program and related product liability litigation. Changes to these accruals may be required in the future as additional information becomes available. Claims for personal injury have also been made against DePuy and Johnson & Johnson relating to DePuy's PINNACLE ® Acetabular Cup System used in hip replacement surgery. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom. The Company has established an accrual for defense costs in connection with product liability litigation associated with DePuy's PINNACLE ® Acetabular Cup System. Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Southern District of West Virginia. In addition, class actions and individual personal injury cases or claims have been commenced in countries outside of the United States, including Australia, Belgium, Canada, England, Israel, Italy, the Netherlands, Scotland and Venezuela, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. The Company has established an accrual with respect to product liability litigation associated with Ethicon's pelvic mesh products. Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established an accrual with respect to product liability litigation associated with RISPERDAL ® . Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of XARELTO ® , an oral anticoagulant. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States and many cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania. Class action lawsuits also have been filed in Canada. The Company has established an accrual for defense costs in connection with product liability litigation associated with XARELTO ® . Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of JOHNSON'S ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri and New Jersey. The Company has established an accrual for defense costs in connection with product liability litigation associated with JOHNSON'S ® Baby Powder. Changes to this accrual may be required in the future as additional information becomes available. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In November 2007, Roche Diagnostics Operations, Inc., et al. (Roche) filed a patent infringement lawsuit against LifeScan, Inc. (LifeScan) in the United States District Court for the District of Delaware, alleging LifeScan's OneTouch ® Line of Blood Glucose Monitoring Systems infringe two patents related to the use of microelectrode sensors. Roche is seeking monetary damages and injunctive relief. In September 2009, LifeScan obtained a favorable ruling on claim construction that precluded a finding of infringement. Roche appealed and the Court of Appeals reversed the District Court's ruling on claim construction and remanded the case to the District Court for new findings on the issue. In December 2014, the District Court ruled in LifeScan's favor and reinstated the original claim construction. In February 2015, Roche appealed the ruling, and in February 2016, oral argument took place at the Court of Appeals. In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVC) in the United States District Court for the Eastern District of Texas alleging that JJVC's manufacture and sale of its ACUVUE ADVANCE ® and ACUVUE OASYS ® Hydrogel Contact Lenses infringe their U.S. Patent No. 5,712,327 (the '327 patent). Rembrandt is seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida. In May 2012, the jury returned a verdict holding that neither of the accused lenses infringes the '327 patent. Rembrandt appealed, and in August 2013, the United States Court of Appeals for the Federal Circuit affirmed the District Court's judgment. Rembrandt asked the District Court to grant it a new trial based on alleged new evidence, and in July 2014, the District Court denied Rembrandt’s motion. Rembrandt appealed and the Court of Appeals overturned that ruling in April 2016 and remanded the case to the District Court for a new trial. JJVC filed a motion to reconsider the decision, which was denied. In December 2009, the State of Israel filed a lawsuit in the District Court in Tel Aviv Jaffa against Omrix Biopharmaceuticals, Inc. and various affiliates (Omrix). In the lawsuit, the State claims that an employee of a government-owned hospital was the inventor on several patents related to fibrin glue technology that the employee developed while he was a government employee. The State claims that he had no right to transfer any intellectual property to Omrix because it belongs to the State. The State is seeking damages plus royalties on QUIXIL™ and EVICEL ® products, or alternatively, transfer of the patents to the State. The case remains active, but no trial date has been set. In September 2011, LifeScan, Inc. (LifeScan) filed a lawsuit against Shasta Technologies, LLC (Shasta), Instacare Corp (now Pharmatech Solutions, Inc. (Pharmatech)) and Conductive Technologies, Inc. (Conductive) in the United States District Court for the Northern District of California for patent infringement and false advertising for the making and marketing of a strip for use in LifeScan's OneTouch ® Blood Glucose Meters. The defendants alleged that the three LifeScan patents-in-suit are invalid and challenged the validity of the asserted patents in the United States Patent and Trademark Office (USPTO). In April 2013, the defendants brought counterclaims for alleged antitrust violations and false advertising and those claims were stayed pending resolution of the patent infringement case. The validity of two of the patents was confirmed by the USPTO, but the USPTO determined that the third patent, U.S. Patent No. 7,250,105, is invalid. LifeScan lost an appeal of that decision, but is seeking a rehearing. LifeScan entered into a settlement agreement with Shasta and Conductive. A motion brought by Pharmatech for summary judgment of patent invalidity was denied. In April 2016, LifeScan and Pharmatech entered into a settlement agreement and the case was dismissed. LifeScan filed a patent infringement lawsuit against UniStrip Technologies, LLC (UniStrip) in the United States District Court for the District of North Carolina in May 2014, alleging that the making and marketing of UniStrip’s strips for use in LifeScan’s blood glucose monitors infringe U.S. Patent Nos. 6,241,862 (the ‘862 patent) and 7,250,105 (the ‘105 patent). In August 2014, the USPTO determined that the ‘105 patent is invalid. In January 2016, the invalidity decision was upheld on appeal. LifeScan filed a motion for rehearing, which was denied. In July 2014, UniStrip brought a lawsuit against LifeScan in the United States District Court for the Eastern District of Pennsylvania, alleging antitrust violations relating to marketing practices for LifeScan strips. In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that all of Cordis's sales of the CYPHER ™ and CYPHER SELECT ™ Stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Medinol is seeking damages and attorney's fees. After trial in January 2014, the District Court dismissed the case, finding Medinol unreasonably delayed bringing its claims, and Medinol did not appeal the decision. In September 2014, the District Court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol's appeal of this decision has been dismissed. Medinol has filed a petition for review with the United States Supreme Court. Following the divestiture of Cordis, the Company retains any liability that may result from this case. Pharmaceutical In 2012 and 2013, Noramco, Inc. (Noramco) moved to intervene in several patent infringement lawsuits filed in the United States District Court for the Southern District of New York by Purdue Pharma L.P. and others (Purdue) against Noramco oxycodone customers, Impax Laboratories, Inc. (Impax), Teva Pharmaceuticals USA, Inc. (Teva), Amneal Pharmaceuticals, LLC (Amneal), Watson Laboratories, Inc.- Florida (Watson) and Andrx Labs, LLC (Andrx). The lawsuits are in response to the defendants' respective Abbreviated New Drug Applications seeking approval to market generic extended release oxycodone products before the expiration of certain Purdue patents. Three of the asserted patents relate to oxycodone and processes for making oxycodone, and Noramco agreed to defend the lawsuits on behalf of Impax, Teva, Amneal, Watson, and Andrx. In April 2013, Watson and Andrx entered into a settlement with Purdue. The trial against Impax and Teva (and others) took place in September 2013, and Noramco defended Teva and Impax. In November 2013, Impax entered into a settlement with Purdue, and in December 2014, Teva entered into a settlement with Purdue. The District Court issued a decision in January 2014 invalidating the relevant Purdue patents and, based on that decision, subsequently dismissed the lawsuit against Amneal (and other parties not defended by Noramco). Purdue appealed the Court's decision. In February 2016, the Federal Circuit affirmed the District Court decision invalidating the Purdue patents. Purdue filed a petition for rehearing and the petition was denied. In December 2015, Purdue filed another patent infringement action against Amneal in the District of Delaware asserting, among others, the three above-referenced patents and a newly issued patent relating to oxycodone and processes for making oxycodone. Noramco was divested in July 2016 and, as a result, the Company is no longer involved in the defense of these actions. Johnson & Johnson acquired the prostate cancer business of Aragon Pharmaceuticals, Inc. (Aragon), including ARN-509, a compound being tested for treatment of prostate cancer, in September 2013. Prior to the acquisition, in May 2011, Medivation, Inc. (Medivation) had sued Aragon and the University of California seeking rights to ARN-509. In December 2012, the state court granted summary judgment to Aragon on Medivation's claims, awarding the rights of the ARN-509 compound to Aragon, and in January 2013, the Court dismissed the case against Aragon. Medivation has appealed. In April 2016, Morphosys AG, a German biotech company, filed a patent infringement lawsuit against Janssen Biotech, Inc. (JBI), Genmab U.S. Inc. and Genmab A/S (collectively, Genmab) in the United States District Court for the District of Delaware, alleging that JBI’s manufacture and sale of DARZALEX ® (daratumumab) willfully infringes its U.S. Patent No. 8,263,746. Morphosys is seeking money damages. JBI licenses patents and the commercial rights to DARZALEX ® from Genmab. In June 2016, JBI filed a motion to dismiss the lawsuit. REMICADE ® Related Cases U.S. Proceedings In September 2013, Janssen Biotech, Inc. (JBI) and NYU Langone Medical Center (NYU) received an Office Action from the United States Patent and Trademark Office (USPTO) rejecting the claims in U.S. Patent No. 6,284,471 relating to REMICADE ® (the '471 patent) in a reexamination proceeding instituted by a third party. The '471 patent is co-owned by JBI and NYU, and NYU granted JBI an exclusive license to NYU’s rights under the patent. The '471 patent in the United States expires in September 2018. Following several office actions by the patent examiner, including two further rejections, and responses by JBI, the USPTO issued a further action maintaining its rejection of the '471 patent. In May 2015, JBI filed a notice of appeal to the USPTO's Patent Trial and Appeal Board, and the appeal is currently pending. The '471 patent remains a valid and enforceable patent as it undergoes reexamination at the USPTO. In August 2014, Celltrion Healthcare Co. Ltd. and Celltrion Inc. (together, Celltrion) filed an application with the U.S. Food and Drug Administration (FDA) for approval to make and sell its own biosimilar version of REMICADE ® . In March 2015, JBI filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira Healthcare Corporation (Hospira), which has exclusive U.S. marketing rights for Celltrion's biosimilar version of REMICADE ® , seeking a declaratory judgment that their biosimilar product infringes or potentially infringes several JBI patents and that defendants failed to comply with certain procedural requirements of the Biologics Price Competition and Innovation Act (BPCIA). In addition, JBI moved for an injunction to prohibit Celltrion and Hospira from launching their biosimilar product until 180 days after they had given JBI a Notice of Commercial Marketing under the BPCIA, such notice not to be given before FDA approval of Celltrion's product. JBI's motion to stay all proceedings in the District Court with respect to the ‘471 patent, pending the outcome of the USPTO reexamination proceeding discussed above, was denied in May 2016. In February 2016, Celltrion and Hospira filed two motions for summary judgment of invalidity of the ‘471 patent, which will be argued in August 2016. In April 2016, the FDA approved Celltrion’s biosimilar version of REMICADE ® for sale in the United States. Celltrion and Hospira have agreed not to launch their biosimilar product before October 3, 2016, 180 days after the FDA's approval of their biosimilar product, thereby eliminating litigation of the issue of the 180-day Notice of Commercial Marketing under the BPCIA. In June 2016, JBI filed two new patent infringement lawsuits asserting U.S. Patent No. 7,598,083 (the '083 patent), one against Celltrion in the United States District Court for the District of Massachusetts and the other against HyClone Laboratories, Inc., the manufacturer of the cell culture media that Celltrion uses to make its biosimilar product, in the United States District Court for the District of Utah. Although the '083 patent is already asserted in the existing lawsuit against Celltrion, the new lawsuit against Celltrion expands the claims to include any use of the cell media made in the United States to manufacture Celltrion's biosimilar. The new lawsuit against Celltrion has been consolidated with the existing Massachusetts lawsuit. The Court has scheduled a claim construction hearing regarding the '083 patent for August 2016. In the United States, if either of the REMICADE ® related patents discussed above is found to be invalid following all appeals, such patent could not be relied upon to prevent the introduction of biosimilar versions of REMICADE ® . Biosimilar versions of REMICADE ® have been introduced in certain markets outside the United States, resulting in a reduction in sales of REMICADE ® in those markets. The timing of the possible introduction of a biosimilar version of REMICADE ® in the United States is subject to enforcement of patent rights and compliance with the 180-day Notice of Commercial Marketing provisions of the BPCIA. There is a risk that Celltrion and Hospira could launch their biosimilar version of REMICADE ® on or after October 3, 2016, even though one or more valid patents are in place and JBI will continue to assert its patent rights. Introduction to the U.S. market of a biosimilar version of REMICADE ® will result in a reduction in U.S. sales of REMICADE ® . Canadian Proceedings In March 2013, Hospira filed an impeachment proceeding against The Kennedy Institute of Rheumatology (Kennedy) challenging the validity of a Canadian patent related to REMICADE ® (a Feldman patent), which is exclusively licensed to JBI. In October 2013, Kennedy, along with JBI, Janssen Inc. (Janssen) and Cilag GmbH International (both affiliates of JBI), filed a counterclaim for infringement against Celltrion and Hospira. The counterclaim alleges that the products described in Celltrion’s and Hospira’s marketing applications to Health Canada for their subsequent entry biologics (SEB) to REMICADE ® would infringe the Feldman patents owned by Kennedy. Discovery in the patent action is ongoing, and trial has been scheduled for September 2016. In January 2014, Health Canada approved Celltrion’s SEB to REMICADE ® , allowing Celltrion to market its biosimilar version of REMICADE ® in Canada, regardless of the pending patent action. In June 2014, Health Canada approved Hospira’s SEB to REMICADE ® . In July 2014, Janssen filed a lawsuit to compel the Canadian Minister of Health to withdraw the Notice of Compliance for Hospira’s SEB because Hospira did not serve a Notice of Allegation on Janssen to address the patent listed by Janssen on the Patent Register. In March 2015, the parties entered into a settlement agreement whereby Health Canada agreed to a Consent Judgment setting aside Hospira’s Notice of Compliance, subject to Health Canada's appeal, which was filed in June 2015. Nevertheless, Hospira began marketing a biosimilar version of REMICADE ® as a distributor under Celltrion's Notice of Compliance. A hearing on the appeal concluded in June 2016 and the parties are awaiting a decision. In Canada, if any of the REMICADE ® related patents discussed above is found to be invalid following all appeals, such patent could not be relied upon to prevent the further introduction of biosimilar versions of REMICADE ® . Litigation Against Filers of Abbreviated New Drug Applications (ANDAs) The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA, or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson & Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of the applicable patents. In the event the subsidiaries are not successful in these actions, or the statutory 30-month stays of the ANDAs expire before the United States District Court rulings are obtained, the third-party companies involved will have the ability, upon approval of the FDA, to introduce generic versions of the products at issue to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. PREZISTA ® In November 2010, Tibotec, Inc. (predecessor-in-interest to Janssen Products, LP) and Tibotec Pharmaceuticals (predecessor-in-interest to Janssen Sciences Ireland UC) (individually or collectively, with one or more affiliates and successors-in-interest, Janssen) filed a series of patent infringement lawsuits, relating to several patents owned by Janssen or licensed to Janssen from G.D. Searle, against Lupin, Ltd. and Lupin Pharmaceuticals, Inc. (together, Lupin) in the United States District Court for the District of New Jersey in response to Lupin's ANDA seeking approval to market a generic version of Tibotec's PREZISTA ® product in various dosage strengths before the expiration of patents relating to PREZISTA ® . In June 2013, Lupin, agreed not to seek FDA approval of its ANDA until the November 2017 expiration of the G.D. Searle patents. After a trial regarding the remaining patents, the Court issued a decision in August 2014, holding that the asserted patents are valid and would be infringed by Lupin's marketing of its proposed products. Lupin appealed. In May 2013, Lupin notified Janssen that it filed an ANDA seeking approval to market a new dosage strength of its generic version of PREZISTA ® . In response, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey, alleging that Lupin's new dosage strength would infringe the same patents that Janssen is asserting against Lupin in the original action. In March 2014, Janssen filed a patent infringement lawsuit against Lupin in the United States District Court for the District of New Jersey, alleging infringement of United States Patent No. 8,518,987 (the ‘987 patent). In January 2015, the Court stayed these cases pending Lupin's appeal of the Court's August 2014 decision in the first action. In April 2015, Lupin filed a petition for Inter Partes review in the United States Patent and Trademark Office (USPTO) seeking to invalidate the ‘987 patent, which was denied in October 2015. In January 2016, Lupin amended its ANDA to reflect a new formulation of darunavir that Lupin alleges does not infringe the relevant Janssen patents. In February 2016, Janssen filed a lawsuit in the United States District Court for the District of New Jersey asserting that Lupin’s new formulation of darunavir infringes the relevant Janssen patents. In the above lawsuits, Janssen sought orders enjoining Lupin from marketing its generic versions of PREZISTA ® before the expiration of the relevant patents. In May 2016, Janssen and Lupin entered into a confidential settlement agreement, pursuant to which the above lawsuits have been dismissed. CONCERTA ® In December 2014, Janssen Inc. and ALZA Corporation filed a Notice of Application against Actavis Pharma Company (Actavis) in response to Actavis’ Notice of Allegation seeking approval to market a generic version of CONCERTA ® before the expiration of Canadian Patent No. 2,264,852 (the ‘852 patent). The hearing is scheduled for September 2016. Janssen and ALZA are seeking an order enjoining Actavis from marketing its generic version of CONCERTA ® before the expiration of the ‘852 patent. ZYTIGA ® In June and July 2015, Janssen Biotech, Inc. (JBI) received notices of paragraph IV certification from several companies advising of their respective ANDAs seeking approval for a generic version of ZYTIGA ® before the expiration of one or more patents relating to ZYTIGA ® . In July 2015, JBI, Janssen Oncology, Inc. (Janssen Oncology) and Janssen Research & Development, LLC (collectively, Janssen) and BTG International Ltd. (BTG) filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against several generic ANDA applicants (and certain of their affiliates and/or suppliers) in response to their respective ANDAs seeking approval to market a generic version of ZYTIGA ® before the expiration of United States Patent Nos. 5,604,213 (the '213 patent) (expiring December 2016) and/or 8,822,438 (the '438 patent) (expiring August 2027). The generic companies include Actavis Laboratories, FL, Inc. (Actavis); Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); Apotex Inc. and Apotex Corp. (coll

Restructuring (Notes)

Restructuring (Notes)	6 Months Ended
	Jul. 03, 2016
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company announced restructuring actions in its Medical Devices segment to better serve the needs of patients and customers in today’s evolving healthcare marketplace. The Company is undertaking actions to strengthen its go-to-market model, accelerate the pace of innovation, further prioritize key platforms and geographies, and streamline operations while maintaining high quality standards. The Company estimates that, in connection with its plans, it will record pre-tax restructuring charges of approximately $2.0 billion to $2.4 billion , most of which are expected to be incurred by 2017. In the fiscal six months of 2016, the Company recorded a pre-tax charge of $278 million , of which $24 million was included in cost of products sold and $20 million was included in other (income) expense. See table below for additional details. Total restructuring charges of $868 million have been recorded since the restructuring has been announced. Additionally, as part of the plan, the Company expects that the restructuring actions will result in position eliminations of approximately 4 to 6 percent of the Medical Devices segment’s global workforce over the next two years, subject to any consultation procedures in countries, where required. Approximately 900 positions have been eliminated since the restructuring has been announced. The Company estimates that approximately one half of the cumulative pre-tax costs will result in cash outlays, including approximately $500 million of employee severance. Approximately one half of the cumulative pre-tax costs are non-cash, relating primarily to facility rationalization, inventory write-offs and intangible asset write-offs. The following table summarizes the severance related reserves and the associated spending under this initiative through the first fiscal six months of 2016: (Dollars in Millions) Severance Asset Write-offs Other Total Reserve balance, January 3, 2016 $ 484 — 17 501 Current year activity: Charges — 150 128 278 Cash payments (56 ) — (142 ) (198 ) Settled without cash — (150 ) — (150 ) Reserve balance, July 3, 2016* $ 428 — 3 431 *Cash outlays for severance are expected to be substantially paid out over the next 24 months in accordance with the Company's plans and local laws.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	6 Months Ended
	Jul. 03, 2016
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as current marketable securities.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 03, 2016
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) July 3, 2016 January 3, 2016 Raw materials and supplies $ 952 936 Goods in process 1,984 2,241 Finished goods 5,587 4,876 Total inventories $ 8,523 8,053

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jul. 03, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets and Goodwill	(Dollars in Millions) July 3, 2016 January 3, 2016 Intangible assets with definite lives: Patents and trademarks — gross $ 8,633 8,299 Less accumulated amortization 4,974 4,745 Patents and trademarks — net 3,659 3,554 Customer relationships and other intangibles — gross 17,799 17,583 Less accumulated amortization 6,242 5,816 Customer relationships and other intangibles — net 11,557 11,767 Intangible assets with indefinite lives: Trademarks 7,085 7,023 Purchased in-process research and development 3,393 3,420 Total intangible assets with indefinite lives 10,478 10,443 Total intangible assets — net $ 25,694 25,764
Goodwill	Goodwill as of July 3, 2016 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at January 3, 2016 $ 7,240 2,889 11,500 21,629 Goodwill, related to acquisitions 225 — 180 405 Goodwill, related to divestitures — (10 ) — (10 ) Currency translation/Other 50 11 19 80 Goodwill, net at July 3, 2016 $ 7,515 2,890 11,699 22,104

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 03, 2016
Fair Value Disclosures [Abstract]
Summary of designated derivatives	The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal second quarters in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Second Quarters Ended Cash Flow Hedges By Income Statement Caption July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Sales to customers (3) $ (27 ) 37 (3 ) (30 ) — (1 ) Cost of products sold (3) (178 ) 52 13 47 (2 ) 14 Research and development expense (3) 12 (7 ) (1 ) 7 (1 ) — Interest (income)/Interest expense, net (4) (3 ) 7 7 — — — Other (income) expense, net (3) (5) (54 ) (28 ) (6 ) 19 — 1 Total $ (250 ) 61 10 43 (3 ) 14 The following table is a summary of the activity related to derivatives designated as cash flow hedges for the first fiscal six months in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Six Months Ended Cash Flow Hedges By Income Statement Caption July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Sales to customers (3) $ (27 ) (55 ) (21 ) (71 ) — (2 ) Cost of products sold (3) (222 ) (116 ) (8 ) 116 (6 ) 14 Research and development expense (3) (95 ) (3 ) (96 ) (9 ) (1 ) — Interest (income)/Interest expense, net (4) 9 (29 ) 15 (3 ) — — Other (income) expense, net (3) (5) (106 ) 69 (2 ) 42 (3 ) 1 Total $ (441 ) (134 ) (112 ) 75 (10 ) 13 All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts
Financial assets and liabilities at fair value	The Company’s significant financial assets and liabilities measured at fair value as of July 3, 2016 and January 3, 2016 were as follows: July 3, 2016 January 3, 2016 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 279 — 279 452 Interest rate contracts (2)(4)(7) — 55 — 55 28 Total — 334 — 334 480 Liabilities: Forward foreign exchange contracts (8) — 569 — 569 358 Interest rate contracts (3)(4)(8) — 314 — 314 241 Equity collar contracts (8)(9) — 108 — 108 — Total — 991 — 991 599 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 28 — 28 33 Liabilities: Forward foreign exchange contracts (8) — 62 — 62 41 Available For Sale Other Investments: Equity investments (5) 1,276 — — 1,276 1,494 Debt securities (6) $ — 12,046 — 12,046 8,316 (1) 2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million , which are classified as Level 1. (2) Includes $41 million and $20 million of non-current other assets for July 3, 2016 and January 3, 2016, respectively. (3) Includes $314 million and $239 million of non-current other liabilities for July 3, 2016 and January 3, 2016, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets with the exception of $272 million of current other assets for July 3, 2016 . The carrying amount of the equity investments were $530 million and $528 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized gains were $767 million and $979 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized losses were $21 million and $13 million as of July 3, 2016 and January 3, 2016, respectively. (6) Classified as current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable. (9) Includes $41 million of non-current other liabilities for July 3, 2016 .
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of July 3, 2016 comprised: July 3, 2016 (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 1,619 — — 1,619 1,619 U.S. Gov't Securities (1) 6,548 1 — 6,549 900 5,648 Other Sovereign Securities (1) 2,494 — — 2,494 1,359 1,135 U.S. Reverse repurchase agreements (1) 11,288 — — 11,288 9,587 1,701 Other Reverse repurchase agreements (1) 1,600 — — 1,600 1,600 Corporate debt securities (1) 4,598 1 — 4,599 1,456 3,142 Money market funds 882 — — 882 882 Time deposits (1) 1,237 — — 1,237 1,237 Subtotal 30,266 2 — 30,268 18,640 11,626 Unrealized Gain Unrealized Loss Gov't securities 10,036 176 — 10,212 — 10,212 Corporate debt securities 1,818 17 (1 ) 1,834 — 1,834 Equity investments 37 246 (11 ) 272 — 272 Subtotal Available for Sale (2) $ 11,891 439 (12 ) 12,318 — 12,318 Total cash, cash equivalents and current marketable securities 18,640 23,944 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Financial assets and liabilities not measured at fair value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July 3, 2016 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 1,708 1,708 Non-Current Debt 5.55% Debentures due 2017 999 1,053 1.125% Notes due 2017 703 709 5.15% Debentures due 2018 899 975 1.65% Notes due 2018 609 620 4.75% Notes due 2019 (1B Euro 1.1098) 1,105 1,286 1.875% Notes due 2019 514 528 0.89% Notes due 2019 299 300 1.125% Notes due 2019 698 704 3% Zero Coupon Convertible Subordinated Debentures due in 2020 110 183 2.95% Debentures due 2020 545 585 3.55% Notes due 2021 447 492 2.45% Notes due 2021 348 371 1.65% Notes due 2021 997 1,015 0.250% Notes due 2022 (1B Euro 1.1098) 1,105 1,123 6.73% Debentures due 2023 249 335 3.375% Notes due 2023 808 905 2.05% Notes due 2023 497 510 0.650% Notes due 2024 (750MM Euro 1.1098) 827 848 5.50% Notes due 2024 (500 MM GBP 1.3418) 664 879 2.45% Notes due 2026 1,989 2,063 1.150% Notes due 2028 (750MM Euro 1.1098) 823 857 6.95% Notes due 2029 296 444 4.95% Debentures due 2033 497 643 4.375% Notes due 2033 857 1,039 1.650% Notes due 2035 (1.5B Euro 1.1098) 1,645 1,811 3.55% Notes due 2036 986 1,096 5.95% Notes due 2037 990 1,472 5.85% Debentures due 2038 695 1,031 4.50% Debentures due 2040 537 680 4.85% Notes due 2041 296 387 4.50% Notes due 2043 495 617 3.70% Notes due 2046 1,970 2,251 Other 36 36 Total Non-Current Debt $ 24,535 27,848

Pensions and Other Postretire24

Pensions and Other Postretirement Benefits (Tables)	6 Months Ended
	Jul. 03, 2016
Compensation and Retirement Disclosure [Abstract]
Components of net periodic benefit cost	Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal second quarters of 2016 and 2015 include the following components: Fiscal Second Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Service cost $ 226 249 55 65 Interest cost 233 248 39 46 Expected return on plan assets (493 ) (455 ) (1 ) (1 ) Amortization of prior service cost/(credit) (1 ) 1 (8 ) (9 ) Recognized actuarial losses 124 187 34 50 Curtailments and settlements 4 — — — Net periodic benefit cost $ 93 230 119 151 Fiscal Six Months Ended Retirement Plans Other Benefit Plans (Dollars in Millions) July 3, 2016 June 28, 2015 July 3, 2016 June 28, 2015 Service cost $ 452 497 110 129 Interest cost 466 497 79 93 Expected return on plan assets (985 ) (910 ) (3 ) (3 ) Amortization of prior service cost/(credit) — 1 (16 ) (17 ) Recognized actuarial losses 248 374 68 100 Curtailments and settlements 5 4 — — Net periodic benefit cost $ 186 463 238 302

Accumulated Other Comprehensi25

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jul. 03, 2016
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 3, 2016 $ (8,435 ) 604 (5,298 ) (36 ) (13,165 ) Net change 584 6 197 (329 ) 458 July 3, 2016 $ (7,851 ) 610 (5,101 ) (365 ) (12,707 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jul. 03, 2016
Earnings Per Share [Abstract]
Reconciliation of basic net earnings per share to diluted net earnings per share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal second quarters ended July 3, 2016 and June 28, 2015 : Fiscal Second Quarters Ended (Shares in Millions) July 3, 2016 June 28, 2015 Basic net earnings per share $ 1.46 1.63 Average shares outstanding — basic 2,745.4 2,772.3 Potential shares exercisable under stock option plans 146.3 151.4 Less: shares which could be repurchased under treasury stock method (99.2 ) (113.9 ) Convertible debt shares 1.7 2.2 Average shares outstanding — diluted 2,794.2 2,812.0 Diluted net earnings per share $ 1.43 1.61 The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal six months ended July 3, 2016 and June 28, 2015 : Fiscal Six Months Ended (Shares in Millions) July 3, 2016 June 28, 2015 Basic net earnings per share $ 3.07 3.18 Average shares outstanding — basic 2,751.4 2,777.7 Potential shares exercisable under stock option plans 145.8 151.4 Less: shares which could be repurchased under treasury stock method (98.0 ) (110.3 ) Convertible debt shares 1.7 2.2 Average shares outstanding — diluted 2,800.9 2,821.0 Diluted net earnings per share $ 3.02 3.13

Segments of Business and Geog27

Segments of Business and Geographic Areas (Tables)	6 Months Ended
	Jul. 03, 2016
Segment Reporting [Abstract]
Sales By Segment Of Business	Fiscal Second Quarters Ended (Dollars in Millions) July 3, June 28, Percent Change Consumer United States $ 1,384 1,355 2.1 % International 2,035 2,128 (4.4 ) Total 3,419 3,483 (1.8 ) Pharmaceutical United States 5,144 4,543 13.2 International 3,510 3,403 3.1 Total 8,654 7,946 8.9 Medical Devices United States 3,044 3,013 1.0 International 3,365 3,345 0.6 Total 6,409 6,358 0.8 Worldwide United States 9,572 8,911 7.4 International 8,910 8,876 0.4 Total $ 18,482 17,787 3.9 % Fiscal Six Months Ended (Dollars in Millions) July 3, June 28, Percent Change Consumer United States $ 2,742 2,714 1.0 % International 3,872 4,159 (6.9 ) Total 6,614 6,873 (3.8 ) Pharmaceutical United States 10,081 8,914 13.1 International 6,751 6,758 (0.1 ) Total 16,832 15,672 7.4 Medical Devices United States 6,070 5,975 1.6 International 6,448 6,641 (2.9 ) Total 12,518 12,616 (0.8 ) Worldwide United States 18,893 17,603 7.3 International 17,071 17,558 (2.8 ) Total $ 35,964 35,161 2.3 %
Operating profit by segment of business	Fiscal Second Quarters Ended (Dollars in Millions) July 3, June 28, Percent Change Consumer $ 571 317 80.1 % Pharmaceutical (1) 3,687 4,122 (10.6 ) Medical Devices (2) 939 1,584 (40.7 ) Segments operating profit 5,197 6,023 (13.7 ) Less: Expense not allocated to segments (3) 293 282 Worldwide income before tax $ 4,904 5,741 (14.6 )% Fiscal Six Months Ended (Dollars in Millions) July 3, 2016 June 28, 2015 Percent Change Consumer $ 1,137 961 18.3 % Pharmaceutical (1) 7,031 7,084 (0.7 ) Medical Devices (2) 2,515 3,805 (33.9 ) Segments operating profit 10,683 11,850 (9.8 ) Less: Expense not allocated to segments (3) 485 534 Worldwide income before taxes $ 10,198 11,316 (9.9 )% (1) Includes litigation expense of $136 million recorded in the fiscal six months of 2015. Includes a gain of $981 million recorded in the fiscal second quarter and first fiscal six months of 2015 from the divestiture of the U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution. Includes a positive adjustment of $539 million and $403 million to previous reserve estimates in the fiscal six months of 2016 and 2015, respectively. Includes a positive adjustment of $342 million and $199 million to previous reserve estimates in the fiscal second quarter of 2016 and 2015, respectively. (2) Includes a restructuring charge of $141 million and $278 million in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $570 million and $676 million recorded in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $134 million in the fiscal second quarter of 2015 and a net litigation gain of $404 million primarily related to a litigation settlement agreement with Guidant recorded in the fiscal six months of 2015. The fiscal six months of 2015 included $148 million for costs associated with the DePuy ASR TM Hip program. (3) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Fiscal Second Quarters Ended (Dollars in Millions) July 3, 2016 June 28, 2015 Percent Change United States $ 9,572 8,911 7.4 % Europe 4,090 4,151 (1.5 ) Western Hemisphere, excluding U.S. 1,542 1,501 2.7 Asia-Pacific, Africa 3,278 3,224 1.7 Total $ 18,482 17,787 3.9 % Fiscal Six Months Ended (Dollars in Millions) July 3, 2016 June 28, 2015 Percent Change United States $ 18,893 17,603 7.3 % Europe 7,937 8,191 (3.1 ) Western Hemisphere, excluding U.S. 2,873 3,140 (8.5 ) Asia-Pacific, Africa 6,261 6,227 0.5 Total $ 35,964 35,161 2.3 %

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jul. 03, 2016
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated spending under this initiative through the first fiscal six months of 2016: (Dollars in Millions) Severance Asset Write-offs Other Total Reserve balance, January 3, 2016 $ 484 — 17 501 Current year activity: Charges — 150 128 278 Cash payments (56 ) — (142 ) (198 ) Settled without cash — (150 ) — (150 ) Reserve balance, July 3, 2016* $ 428 — 3 431 *Cash outlays for severance are expected to be substantially paid out over the next 24 months in accordance with the Company's plans and local laws.

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 03, 2016	Jul. 03, 2016	Jun. 28, 2015
Tax benefit	$ 123	$ 288
Net Cash Provided by (Used in) Operating Activities		6,753	$ 8,344
Net Cash Provided by (Used in) Financing Activities		1,642	6,002
New Accounting Pronouncement, Early Adoption, Effect | Accounting Standards Update 2016-09, Statutory Tax Withholding Component
Net Cash Provided by (Used in) Operating Activities		262	272
Net Cash Provided by (Used in) Financing Activities		$ 262	$ 272

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jul. 03, 2016	Jan. 03, 2016
Summary of Inventories
Raw materials and supplies	$ 952	$ 936
Goods in process	1,984	2,241
Finished goods	5,587	4,876
Total inventories	$ 8,523	$ 8,053

Intangible Assets and Goodwil31

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Jul. 03, 2016	Jan. 03, 2016
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 10,478	$ 10,443
Total intangible assets - net	25,694	25,764
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	7,085	7,023
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	3,393	3,420
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	8,633	8,299
Less accumulated amortization	4,974	4,745
Finite-Lived Intangible Assets, Net	3,659	3,554
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	17,799	17,583
Less accumulated amortization	6,242	5,816
Finite-Lived Intangible Assets, Net	$ 11,557	$ 11,767

Goodwill By Segment (Details)

Goodwill By Segment (Details) $ in Millions	6 Months Ended
	Jul. 03, 2016USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 21,629
Goodwill, related to acquisitions	405
Goodwill, related to divestitures	(10)
Currency translation/Other	80
Goodwill End of Period	22,104
Consumer
Goodwill [Roll Forward]
Goodwill Beginning of Period	7,240
Goodwill, related to acquisitions	225
Goodwill, related to divestitures	0
Currency translation/Other	50
Goodwill End of Period	7,515
Pharmaceutical
Goodwill [Roll Forward]
Goodwill Beginning of Period	2,889
Goodwill, related to acquisitions	0
Goodwill, related to divestitures	(10)
Currency translation/Other	11
Goodwill End of Period	2,890
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	11,500
Goodwill, related to acquisitions	180
Goodwill, related to divestitures	0
Currency translation/Other	19
Goodwill End of Period	$ 11,699

Intangible Assets and Goodwil33

Intangible Assets and Goodwill (Details Textuals) - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 1,200
Finite-Lived Intangible Assets, Amortization Expense, Year Two	1,200
Finite-Lived Intangible Assets, Amortization Expense, Year Three	1,200
Finite-Lived Intangible Assets, Amortization Expense, Year Four	1,200
Finite-Lived Intangible Assets, Amortization Expense, Year Five	1,200
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	$ 576	$ 619
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	18 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	24 years

Fair Value Measurements (Detail

Fair Value Measurements (Details Textuals) - USD ($) $ in Millions		3 Months Ended		6 Months Ended		12 Months Ended
		Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015	Jan. 03, 2016
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	[1]	$ 1,276		$ 1,276		$ 1,494	[2]
Foreign currency translation		(295)	$ 903	584	$ (1,660)
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		(7,851)		(7,851)		(8,435)
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax		$ (365)		$ (365)		(36)
Maximum Length of Time Hedged in Foreign Currency Cash Flow Hedge				18 months
Fair Value Measurements (Textuals)
Reclassification of foreign exchange contracts into earnings, period				next 12 months
Weighted average interest rate on non-current debt		3.30%		3.30%
Excess Of Fair Value Over Carrying Value Of Debt						1,700
Other income/(expense), net, related to foreign exchange contracts, non hedging		$ (36)	$ 124	$ (41)	$ 40
Interest Rate Contract
Derivative [Line Items]
Derivative notional amounts outstanding		2,200		2,200
Fair Value Measurements (Textuals)
Derivative Liability, Noncurrent		314		314		239
Foreign exchange contracts
Derivative [Line Items]
Derivative notional amounts outstanding		31,600		31,600
Cross currency interest rate swaps
Derivative [Line Items]
Derivative notional amounts outstanding		2,300		2,300
Equity Contract
Derivative [Line Items]
Derivative notional amounts outstanding		500		500
Fair Value Measurements (Textuals)
Derivative Liability, Noncurrent		41		41
Equity Securities [Member]
Derivative [Line Items]
Available-for-sale Securities, Equity Securities		530		530		528
Fair Value Measurements (Textuals)
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		767		767		979
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		21		21		$ 13
Other Current Assets [Member] | Equity Securities [Member]
Derivative [Line Items]
Available-for-sale Securities, Equity Securities		$ 272		272
Other Comprehensive Income (Loss) [Member]
Derivative [Line Items]
Foreign currency translation				$ 116
[1]	Classified as non-current other assets with the exception of $272 million of current other assets for July 3, 2016. The carrying amount of the equity investments were $530 million and $528 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized gains were $767 million and $979 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized losses were $21 million and $13 million as of July 3, 2016 and January 3, 2016, respectively
[2]	2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million, which are classified as Level 1.

Fair Value Measurements (Deta35

Fair Value Measurements (Details) - Designated as Hedging Instrument - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1]	$ (250)	$ 61	$ (441)	$ (134)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1]	10	43	(112)	75
Gain/ (Loss) recognized in Other income/expense	[2]	(3)	14	(10)	13
Foreign exchange contracts | Sales to customers
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	(27)	37	(27)	(55)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	(3)	(30)	(21)	(71)
Gain/ (Loss) recognized in Other income/expense	[2],[3]	0	(1)	0	(2)
Foreign exchange contracts | Cost of products sold
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	(178)	52	(222)	(116)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	13	47	(8)	116
Gain/ (Loss) recognized in Other income/expense	[2],[3]	(2)	14	(6)	14
Foreign exchange contracts | Research and development expense
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	12	(7)	(95)	(3)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	(1)	7	(96)	(9)
Gain/ (Loss) recognized in Other income/expense	[2],[3]	(1)	0	(1)	0
Foreign exchange contracts | Other (income) expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3],[4]	(54)	(28)	(106)	69
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3],[4]	(6)	19	(2)	42
Gain/ (Loss) recognized in Other income/expense	[2],[3],[4]	0	1	(3)	1
Cross currency interest rate swaps | Interest (income)/Interest expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[5]	(3)	7	9	(29)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[5]	7	0	15	(3)
Gain/ (Loss) recognized in Other income/expense	[2],[5]	$ 0	$ 0	$ 0	$ 0
[1]	Effective portion
[2]	Ineffective portion
[3]	Forward foreign exchange contracts
[4]	Includes equity collar contracts
[5]	Cross currency interest rate swaps

Fair Value Measurements (Deta36

Fair Value Measurements (Details 1) - USD ($) $ in Millions		Jul. 03, 2016		Jan. 03, 2016
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		$ 334
Derivatives designated as hedging instruments : Liabilities		991
Available-for-sale Securities, Equity Securities	[1]	1,276		$ 1,494	[2]
Available-for-sale Securities	[3]	12,046		8,316	[2]
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		0
Derivatives designated as hedging instruments : Liabilities		0
Available-for-sale Securities, Equity Securities		1,276	[1]	1,494
Available-for-sale Securities	[3]	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		334		480	[2]
Derivatives designated as hedging instruments : Liabilities		991		599	[2]
Available-for-sale Securities, Equity Securities	[1]	0
Available-for-sale Securities	[3]	12,046
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		0
Derivatives designated as hedging instruments : Liabilities		0
Available-for-sale Securities, Equity Securities	[1]	0
Available-for-sale Securities	[3]	0
Interest Rate Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		2,200
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	55
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	314
Derivative Assets, Noncurrent		41		20
Derivative Liabilities, Noncurrent		314		239
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	0
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	55		28	[2]
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	314		241	[2]
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	0
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	0
Equity Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		500
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	108
Derivative Liabilities, Noncurrent		41
Equity Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	0
Equity Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	108		0	[2]
Equity Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	0
Foreign exchange contracts
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		31,600
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	279
Derivatives designated as hedging instruments : Liabilities	[7]	569
Derivatives not designated as hedging instruments : Assets	[4]	28
Derivatives not designated as hedging instruments : Liabilities	[7]	62
Foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	0
Derivatives designated as hedging instruments : Liabilities	[7]	0
Derivatives not designated as hedging instruments : Assets	[4]	0
Derivatives not designated as hedging instruments : Liabilities	[7]	0
Foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	279		452	[2]
Derivatives designated as hedging instruments : Liabilities	[7]	569		358	[2]
Derivatives not designated as hedging instruments : Assets	[4]	28		33	[2]
Derivatives not designated as hedging instruments : Liabilities	[7]	62		41	[2]
Foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	0
Derivatives designated as hedging instruments : Liabilities	[7]	0
Derivatives not designated as hedging instruments : Assets	[4]	0
Derivatives not designated as hedging instruments : Liabilities	[7]	0
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		2,300
Equity Securities [Member]
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities		530		528
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		767		979
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		21		$ 13
Other Current Assets [Member] | Equity Securities [Member]
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities		$ 272
[1]	Classified as non-current other assets with the exception of $272 million of current other assets for July 3, 2016. The carrying amount of the equity investments were $530 million and $528 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized gains were $767 million and $979 million as of July 3, 2016 and January 3, 2016, respectively. The unrealized losses were $21 million and $13 million as of July 3, 2016 and January 3, 2016, respectively
[2]	2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million, which are classified as Level 1.
[3]	Classified as current marketable securities
[4]	Classified as other current assets
[5]	Includes $41 million and $20 million of non-current other assets for July 3, 2016 and January 3, 2016, respectively.
[6]	Includes cross currency interest rate swaps and interest rate swaps.
[7]	Classified as accounts payable.
[8]	Includes $314 million and $239 million of non-current other liabilities for July 3, 2016 and January 3, 2016, respectively.
[9]	Includes $41 million of non-current other liabilities for July 3, 2016.

Fair Value Measurements - Cash

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions		Jul. 03, 2016	Jan. 03, 2016		Jun. 28, 2015	Dec. 28, 2014
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Estimated Fair Value	[1]	$ 12,046	$ 8,316	[2]
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		18,640	13,732		$ 10,639	$ 14,523
Marketable securities		23,944	$ 24,644
Held-to-maturity Securities
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		30,266
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		2
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		30,268
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		18,640
Marketable securities		11,626
Held-to-maturity Securities | Cash
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		1,619
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		1,619
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		1,619
Held-to-maturity Securities | U.S. Gov't Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	6,548
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		1
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	6,549
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	900
Marketable securities	[3]	5,648
Held-to-maturity Securities | Other Sovereign Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	2,494
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	2,494
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	1,359
Marketable securities	[3]	1,135
Held-to-maturity Securities | U.S. Reverse repurchase agreements(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	11,288
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	11,288
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	9,587
Marketable securities	[3]	1,701
Held-to-maturity Securities | Other Reverse repurchase agreements(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	1,600
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	1,600
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	1,600
Held-to-maturity Securities | Corporate debt securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	4,598
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		1
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	4,599
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	1,456
Marketable securities	[3]	3,142
Held-to-maturity Securities | Money market funds
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		882
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		882
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		882
Held-to-maturity Securities | Time deposits(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	1,237
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	1,237
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	1,237
Available-for-sale Securities
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	11,891
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	439
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	(12)
Available-for-sale Securities - Estimated Fair Value	[4]	12,318
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[4]	0
Marketable securities	[4]	12,318
Available-for-sale Securities | U.S. Gov't Securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	10,036
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	176
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	0
Available-for-sale Securities - Estimated Fair Value	[4]	10,212
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[4]	10,212
Available-for-sale Securities | Corporate debt securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	1,818
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	17
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	(1)
Available-for-sale Securities - Estimated Fair Value	[4]	1,834
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[4]	1,834
Available-for-sale Securities | Equity investments
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	37
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	246
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	(11)
Available-for-sale Securities - Estimated Fair Value	[4]	272
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[4]	$ 272
[1]	Classified as current marketable securities
[2]	2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million, which are classified as Level 1.
[3]	Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings
[4]	Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.

Fair Value Measurements (Deta38

Fair Value Measurements (Details 2) (Details) - USD ($) $ in Millions	Jul. 03, 2016	Jan. 03, 2016
Financial Liabilities
Current Debt	$ 1,708	$ 7,004
Non-Current Debt
Non-Current Debt	24,535	$ 12,857
Carrying Amount
Financial Liabilities
Current Debt	1,708
Non-Current Debt
Non-Current Debt	24,535
Estimate of Fair Value, Fair Value Disclosure
Financial Liabilities
Current Debt	1,708
Non-Current Debt
Non-Current Debt	$ 27,848
5.55% Debentures due 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.55%
5.55% Debentures due 2017 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 999
5.55% Debentures due 2017 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,053
1.125% Notes due 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.125%
1.125% Notes due 2017 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 703
1.125% Notes due 2017 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 709
5.15% Debentures due 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.15%
5.15% Debentures due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 899
5.15% Debentures due 2018 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 975
1.65% Notes due 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.65% Notes due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 609
1.65% Notes due 2018 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 620
4.75% Notes due 2019 (1B Euro 1.1098)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
4.75% Notes due 2019 (1B Euro 1.1098) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,105
4.75% Notes due 2019 (1B Euro 1.1098) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,286
1.875% Notes due 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.875%
1.875% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 514
1.875% Notes due 2019 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 528
0.89% Notes due 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.89%
0.89% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 299
0.89% Notes due 2019 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 300
1.125% Notes due 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.125%
1.125% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 698
1.125% Notes due 2019 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 704
3% Zero Coupon Convertible Subordinated Debentures due in 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.00%
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 110
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 183
2.95% Debentures due 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.95%
2.95% Debentures due 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 545
2.95% Debentures due 2020 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 585
3.55% Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.55%
3.55% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 447
3.55% Notes due 2021 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 492
2.45% Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 348
2.45% Notes due 2021 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 371
1.65% Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.65% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
1.65% Notes due 2021 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,015
0.250% Notes due 2022 (1B Euro 1.1098)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.25%
0.250% Notes due 2022 (1B Euro 1.1098) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,105
0.250% Notes due 2022 (1B Euro 1.1098) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,123
6.73% Debentures due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 249
6.73% Debentures due 2023 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 335
3.375% Notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 808
3.375% Notes due 2023 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 905
2.05% Notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 497
2.05% Notes due 2023 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 510
0.650% Notes due 2024 (750MM Euro 1.1098)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.65%
0.650% Notes due 2024 (750MM Euro 1.1098) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 827
0.650% Notes due 2024 (750MM Euro 1.1098) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 848
5.50% Notes due 2024 (500 MM GBP 1.3418)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.50%
5.50% Notes due 2024 (500 MM GBP 1.3418) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 664
5.50% Notes due 2024 (500 MM GBP 1.3418) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 879
2.45% Notes due 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,989
2.45% Notes due 2026 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 2,063
1.150% Notes due 2028 (750MM Euro 1.1098)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.15%
1.150% Notes due 2028 (750MM Euro 1.1098) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 823
1.150% Notes due 2028 (750MM Euro 1.1098) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 857
6.95% Notes due 2029
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
6.95% Notes due 2029 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 444
4.95% Debentures due 2033
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 497
4.95% Debentures due 2033 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 643
4.375% Notes due 2033
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 857
4.375% Notes due 2033 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,039
1.650% Notes due 2035 (1.5B Euro 1.1098)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.650% Notes due 2035 (1.5B Euro 1.1098) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,645
1.650% Notes due 2035 (1.5B Euro 1.1098) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,811
3.55% Notes due 2036
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 986
3.55% Notes due 2036 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,096
5.95% Notes due 2037
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 990
5.95% Notes due 2037 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,472
5.85% Debentures due 2038
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 695
5.85% Debentures due 2038 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 1,031
4.50% Debentures due 2040
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 537
4.50% Debentures due 2040 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 680
4.85% Notes due 2041
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
4.85% Notes due 2041 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 387
4.50% Notes due 2043
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 617
3.70% Notes due 2046
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,970
3.70% Notes due 2046 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	2,251
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	36
Other | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 36

Income Taxes (Details Textuals)

Income Taxes (Details Textuals) - USD ($) $ in Billions	6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015
Income Tax (Textuals)
Effective Income Tax Rate, Continuing Operations	17.10%	21.90%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	1.70%
Other tax item percent	2.80%
Unrecognized tax benefits	$ 3.1

Pensions and Other Postretire40

Pensions and Other Postretirement Benefits (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 226	$ 249	$ 452	$ 497
Interest cost	233	248	466	497
Expected return on plan assets	(493)	(455)	(985)	(910)
Amortization of prior service cost/(credit)	(1)	1	0	1
Recognized actuarial losses	124	187	248	374
Curtailments and settlements	4	0	5	4
Net periodic benefit cost	93	230	186	463
Other Benefit Plans
Components of net periodic benefit cost
Service cost	55	65	110	129
Interest cost	39	46	79	93
Expected return on plan assets	(1)	(1)	(3)	(3)
Amortization of prior service cost/(credit)	(8)	(9)	(16)	(17)
Recognized actuarial losses	34	50	68	100
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 119	$ 151	$ 238	$ 302

Pensions and Other Postretire41

Pensions and Other Postretirement Benefit (Details Textuals) $ in Millions	6 Months Ended
	Jul. 03, 2016USD ($)
U.S. retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 283
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 14

Accumulated Other Comprehensi42

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Foreign Currency Translation
Beginning Balance			$ (8,435)
Net change	$ (295)	$ 903	584	$ (1,660)
Ending Balance	(7,851)		(7,851)
Gain /(Loss) on Securities
Beginning Balance			604
Net change	144	172	6	230
Ending Balance	610		610
Employee Benefit Plans
Begining Balance			(5,298)
Net change	95	153	197	307
Ending Balance	(5,101)		(5,101)
Gain/(Loss) on Derivatives & Hedges
Beginning Balance			(36)
Net change	(260)	18	(329)	(209)
Ending Balance	(365)		(365)
Total Accumulated Other Comprehensive Income (Loss)
Beginning Balance			(13,165)
Net change	(316)	$ 1,246	458	$ (1,332)
Ending Balance	$ (12,707)		$ (12,707)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares shares in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.46	$ 1.63	$ 3.07	$ 3.18
Average shares outstanding — basic	2,745.4	2,772.3	2,751.4	2,777.7
Potential shares exercisable under stock option plans	146.3	151.4	145.8	151.4
Less: shares which could be repurchased under treasury stock method	(99.2)	(113.9)	(98)	(110.3)
Convertible debt shares	1.7	2.2	1.7	2.2
Average shares outstanding — diluted	2,794.2	2,812	2,800.9	2,821
Diluted net earnings per share	$ 1.43	$ 1.61	$ 3.02	$ 3.13

Segments of Business and Geog44

Segments of Business and Geographic Areas (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Sales by segment of business
Sales	$ 18,482	$ 17,787	$ 35,964	$ 35,161
Percentage Change In Sales By Segment Of Business	3.90%		2.30%
United States
Sales by segment of business
Sales	$ 9,572	8,911	$ 18,893	17,603
Percentage Change In Sales By Segment Of Business	7.40%		7.30%
International
Sales by segment of business
Sales	$ 8,910	8,876	$ 17,071	17,558
Percentage Change In Sales By Segment Of Business	0.40%		(2.80%)
Consumer
Sales by segment of business
Sales	$ 3,419	3,483	$ 6,614	6,873
Percentage Change In Sales By Segment Of Business	(1.80%)		(3.80%)
Consumer | United States
Sales by segment of business
Sales	$ 1,384	1,355	$ 2,742	2,714
Percentage Change In Sales By Segment Of Business	2.10%		1.00%
Consumer | International
Sales by segment of business
Sales	$ 2,035	2,128	$ 3,872	4,159
Percentage Change In Sales By Segment Of Business	(4.40%)		(6.90%)
Pharmaceutical
Sales by segment of business
Sales	$ 8,654	7,946	$ 16,832	15,672
Percentage Change In Sales By Segment Of Business	8.90%		7.40%
Pharmaceutical | United States
Sales by segment of business
Sales	$ 5,144	4,543	$ 10,081	8,914
Percentage Change In Sales By Segment Of Business	13.20%		13.10%
Pharmaceutical | International
Sales by segment of business
Sales	$ 3,510	3,403	$ 6,751	6,758
Percentage Change In Sales By Segment Of Business	3.10%		(0.10%)
Medical Devices
Sales by segment of business
Sales	$ 6,409	6,358	$ 12,518	12,616
Percentage Change In Sales By Segment Of Business	0.80%		(0.80%)
Medical Devices | United States
Sales by segment of business
Sales	$ 3,044	3,013	$ 6,070	5,975
Percentage Change In Sales By Segment Of Business	1.00%		1.60%
Medical Devices | International
Sales by segment of business
Sales	$ 3,365	$ 3,345	$ 6,448	$ 6,641
Percentage Change In Sales By Segment Of Business	0.60%		(2.90%)

Segments of Business and Geog45

Segments of Business and Geographic Areas (Details 1) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges				$ 185	$ 1,034
Restructuring charges		$ 114	$ 0	$ 234	0
Percentage Change in Operating Income Loss		(14.60%)		(9.90%)
Earnings before provision for taxes on income		$ 4,904	5,741	$ 10,198	11,316
Pharmaceutical
Segment Reporting Information [Line Items]
Valuation Allowances and Reserves, Adjustments		342	199	539	403
Gain (Loss) on Sale of Assets and Asset Impairment Charges			981		981
Litigation Expense					136
Medical Devices
Segment Reporting Information [Line Items]
Litigation Expense		570	134	676
Restructuring charges		141		278
Litigation Settlement, Amount					404
Product Liability Accrual, Period Expense					148
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 5,197	6,023	$ 10,683	11,850
Percentage Change in Operating Income Loss		(13.70%)		(9.80%)
Operating Segments [Member] | Consumer
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 571	317	$ 1,137	961
Percentage Change in Operating Income Loss		80.10%		18.30%
Operating Segments [Member] | Pharmaceutical
Segment Reporting Information [Line Items]
Total Segment Operating Income	[1]	$ 3,687	4,122	$ 7,031	7,084
Percentage Change in Operating Income Loss		(10.60%)		(0.70%)
Operating Segments [Member] | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	[2]	$ 939	1,584	$ 2,515	3,805
Percentage Change in Operating Income Loss		(40.70%)		(33.90%)
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income	[3]	$ 293	$ 282	$ 485	$ 534
[1]	Includes litigation expense of $136 million recorded in the fiscal six months of 2015. Includes a gain of $981 million recorded in the fiscal second quarter and first fiscal six months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes a positive adjustment of $539 million and $403 million to previous reserve estimates in the fiscal six months of 2016 and 2015, respectively. Includes a positive adjustment of $342 million and $199 million to previous reserve estimates in the fiscal second quarter of 2016 and 2015, respectively.
[2]	Includes a restructuring charge of $141 million and $278 million in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $570 million and $676 million recorded in the fiscal second quarter and fiscal six months of 2016, respectively. Includes litigation expense of $134 million in the fiscal second quarter of 2015 and a net litigation gain of $404 million primarily related to a litigation settlement agreement with Guidant recorded in the fiscal six months of 2015. The fiscal six months of 2015 included $148 million for costs associated with the DePuy ASRTM Hip program.
[3]	Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Segments of Business and Geog46

Segments of Business and Geographic Areas (Details 2) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Sales by geographic area
Sales	$ 18,482	$ 17,787	$ 35,964	$ 35,161
Percentage Change In Sales By Geographic Area	3.90%		2.30%
UNITED STATES
Sales by geographic area
Sales	$ 9,572	8,911	$ 18,893	17,603
Percentage Change In Sales By Geographic Area	7.40%		7.30%
Europe
Sales by geographic area
Sales	$ 4,090	4,151	$ 7,937	8,191
Percentage Change In Sales By Geographic Area	(1.50%)		(3.10%)
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,542	1,501	$ 2,873	3,140
Percentage Change In Sales By Geographic Area	2.70%		(8.50%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,278	3,224	$ 6,261	6,227
Percentage Change In Sales By Geographic Area	1.70%		0.50%
Medical Devices [Member]
Sales by geographic area
Sales	$ 6,409	6,358	$ 12,518	12,616
Medical Devices [Member] | UNITED STATES
Sales by geographic area
Sales	$ 3,044	$ 3,013	$ 6,070	$ 5,975

Business Combinations and Div47

Business Combinations and Divestitures (Details) - USD ($) $ in Millions	Jul. 18, 2016	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 730	$ 233
Proceeds from Sale of Productive Assets				685	1,193
Gain (Loss) on Sale of Assets and Asset Impairment Charges				$ 185	1,034
API [Member]
Business Acquisition [Line Items]
Proceeds from Sale of Productive Assets		$ 650
Nucynta [Member]
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets			$ 1,050
Pharmaceutical
Business Acquisition [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges			$ 981		$ 981
Vogue International LLC [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired	$ 3,300

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	1 Months Ended		3 Months Ended		6 Months Ended
	May 31, 2014	Mar. 31, 2013patents	Jul. 03, 2016USD ($)claimant	Jun. 28, 2015USD ($)	Jul. 03, 2016USD ($)patentsclaimant
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			2,900		2,900
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			9,100		9,100
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			50,100		50,100
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			13,000		13,000
Xarelto [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			13,900		13,900
Baby Powder [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			1,700		1,700
settled litigation | misdemeanor violation [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Amount | $					$ 20
settled litigation | Forfeiture [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Amount | $					5
Pending Litigation | Baby Powder [Member]
Legal Proceeding (Textuals)
Loss Contingency, New Claims Filed, Number	2
Investigative Demands [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Expense | $					$ 4
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement			8,000		8,000
Roche Diagnostics [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents					2
Medinol Ltd. [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents		4
DePuy ASR U.S.Second Agreement [Member] | Pending Litigation
Legal Proceeding (Textuals)
Number of patients in settlement			1,800		1,800
Medical Devices [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Expense | $			$ 570	$ 134	$ 676

Restructuring (Details)

Restructuring (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016USD ($)	Jun. 28, 2015USD ($)	Jul. 03, 2016USD ($)Employee	Jun. 28, 2015USD ($)	Jan. 03, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 114	$ 0	$ 234	$ 0
Medical Devices [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	141		278
Restructuring charges recorded to date	$ 868		$ 868
Period of workforce reduction			2 years
Number of positions eliminated | Employee			900
Medical Devices [Member] | Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 24
Medical Devices [Member] | Other Income Expense Net [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			20
Medical Devices [Member] | Asset Write-off [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			150
Medical Devices [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			128
Medical Devices [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost					$ 500
Restructuring charges			$ 0
Minimum [Member] | Medical Devices [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost					2,000
Positions eliminated (as a percent)			4.00%
Maximum [Member] | Medical Devices [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost					$ 2,400
Positions eliminated (as a percent)			6.00%

Restructuring (Details 1)

Restructuring (Details 1) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2016	Jun. 28, 2015	Jul. 03, 2016	Jun. 28, 2015
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 114	$ 0	$ 234	$ 0
Medical Devices [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			501
Restructuring charges	141		278
Payments for Restructuring			(198)
Restructuring Reserve, Settled without Cash			(150)
Reserve balance ending	431		431
Medical Devices [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			484
Restructuring charges			0
Payments for Restructuring			(56)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	428		428
Medical Devices [Member] | Asset Write-off [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			0
Restructuring charges			150
Payments for Restructuring			0
Restructuring Reserve, Settled without Cash			(150)
Reserve balance ending	0		0
Medical Devices [Member] | Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			17
Restructuring charges			128
Payments for Restructuring			(142)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	$ 3		$ 3